SCHEMBL14720

SCHEMBL14720

CC(C)(C)OC(=O)Nc1nccs1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.66
L3MBTL1 Q9Y468 2/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
MAPT P10636 1/20 0.55
PKM P14618 2/20 0.53
ALDH1A1 P00352 1/20 0.53
NPC1 O15118 2/20 0.51
ADORA2A P29274 1/20 0.49
NR3C1 P04150 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 1/20 0.49
HIF1A Q16665 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL27988165 0.94 METAP1 (0.60) METAP1L3MBTL1MEN1KMT2AMAPT
SCHEMBL27567716 0.84 METAP1 (0.53) METAP1L3MBTL1MEN1KMT2AMAPT
SCHEMBL29850310 0.84 METAP1 (0.50) METAP1L3MBTL1MEN1KMT2AMAPT
SCHEMBL4286543 0.84 AGER (0.68) METAP1L3MBTL1MEN1KMT2AMAPT
SCHEMBL628283 0.82 L3MBTL1 (0.62) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL19974170 0.82 LMNA (0.56) METAP1L3MBTL1MEN1KMT2AMAPT
SCHEMBL7384478 0.82 HSPA5 (0.62) METAP1L3MBTL1MEN1KMT2A
SCHEMBL31421303 0.79 L3MBTL1 (0.54) METAP1L3MBTL1MEN1KMT2APKM
SCHEMBL8182505 0.78 L3MBTL1 (0.61) METAP1L3MBTL1MEN1KMT2APKM
SCHEMBL6820524 0.78 HSPA5 (0.61) METAP1L3MBTL1PKMALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
CN-115181154-A Pyxinol amide derivative, preparation method thereof and application thereof in field of medicines 烟台大学 2022-10-14 CN claimed
CN-101679370-A Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals GRUENENTHAL GMBH 2010-03-24 CN claimed
WO-2026103747-A1 SALT OF THIAZOLE DERIVATIVE INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2026-05-21 WO disclosed
WO-2026103749-A1 CRYSTAL FORM OF THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2026-05-21 WO disclosed
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12612396-B1 Modulators of beta catenin and uses thereof DEWPOINT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
EP-4711365-A1 THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-03-18 EP disclosed
EP-4662211-A1 G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF Nanjing Huanbo Biotechnology Co., Ltd. (CN) 2025-12-17 EP disclosed
WO-2025245175-A1 MACROCYCLIC HETEROAROMATIC INHIBITORS OF JAK2 AJAX THERAPEUTICS, INC. (US) 2025-11-27 WO disclosed
WO-2025077732-A1 NOVEL INTERLEUKIN-17 INHIBTORS SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2025-04-17 WO disclosed
WO-2005075435-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-08-18 WO disclosed
EP-1448536-A1 CYCLOPROPYL-CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2004-08-25 EP disclosed
US-6686363-B2 EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA KYORIN PHARMACEUTICAL CO., LTD. (JP) 2004-02-03 US disclosed
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK SHARP & DOHME CORP. 2003-12-04 US disclosed
WO-2003048136-A1 CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2003-06-12 WO disclosed
US-5627198-A BLOOD METAL CONCENTRATIONS HAFSLUND NYCOMED PHARMA AKTIENGESELLSCHAFT (AT) 1997-05-06 US disclosed
US-5049558-A Quaternized nitrogen-heterocycle substituted IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-09-17 US disclosed
EP-0164944-B1 CEPHALOSPORIN DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-07-11 EP disclosed
EP-0164944-A1 Cephalosporin derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612396-B1 Modulators of beta catenin and uses thereof CTNNB1, CTNND1, CTNNA1 METAP1 3810/4885L3MBTL1 1247/4885MEN1 1798/4885
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNND1, CTNNA1 METAP1 3810/4885L3MBTL1 1247/4885MEN1 1798/4885
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF ALAD, OXA1L, ECI1 METAP1 2697/4885L3MBTL1 3943/4885MEN1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.